HR POSITIVE/HER-2 NEGATIVE BREAST CANCER
Clinical trials for HR POSITIVE/HER-2 NEGATIVE BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new HR POSITIVE/HER-2 NEGATIVE BREAST CANCER trials appear
Sign up with your email to follow new studies for HR POSITIVE/HER-2 NEGATIVE BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug targets Hard-to-Treat cancers with PIK3CA mutation
Disease control Not yet recruitingThis early-phase study tests an experimental drug called CGT6297 in 90 adults whose advanced solid tumors (including certain breast and endometrial cancers) have a specific genetic change called PIK3CA. The main goals are to check the drug's safety and find the best dose, while a…
Matched conditions: HR POSITIVE/HER-2 NEGATIVE BREAST CANCER
Phase: PHASE1 • Sponsor: Cogent Biosciences, Inc. • Aim: Disease control
Last updated May 13, 2026 16:02 UTC
-
New combo aims to wipe out breast cancer before surgery
Disease control Not yet recruitingThis study tests whether adding an immune-boosting drug (eftilagimod alpha) to standard chemotherapy before surgery can eliminate more breast cancer in people with early-stage HR+/HER2- breast cancer. About 50 participants will receive the drug combination, and researchers will c…
Matched conditions: HR POSITIVE/HER-2 NEGATIVE BREAST CANCER
Phase: PHASE2 • Sponsor: George Washington University • Aim: Disease control
Last updated May 11, 2026 20:40 UTC